Semaglutide may be inappropriate for people with label-listed contraindications, certain pregnancy or breastfeeding situations, or medical histories that raise concern for serious gastrointestinal, gallbladder, pancreatic, kidney, or mental health complications
GLP-1 receptor agonists stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning they promote insulin release primarily when blood glucose levels are elevated
However, compared with native GLP-1, which is rapidly degraded and has a short half-life of approximately 2 min, semaglutide has been structurally modified by the addition of a hydrophilic spacer and a fatty acid side chain, allowing reversible binding to albumin [36]
Your dose may need to go up during your treatment journey